文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

意外性低体温复温治疗对结局的影响:一项多中心前瞻性研究的二次分析

Effects of rewarming therapies on outcomes in accidental hypothermia: A secondary analysis of a multicenter prospective study.
PubMed 文献 · Am J Emerg Med · 2024-02-15
一句话结论在意外性低体温患者中,无任何传统复温技术与28天生存相关,年龄、ADL和SOFA评分等背景因素对预后影响更大。

本研究为ICE-CRASH多中心前瞻性观察研究的二次分析,纳入日本36家三级医院收治的核心体温≤32°C的成人意外性低体温患者371例,均接受传统复温治疗。以28天生存为目标变量进行logistic回归,发现年龄(OR 0.97,95%CI 0.94-1.00)和SOFA评分(OR 0.73,95%CI 0.67-0.81)与生存率降低相关,ADL独立(OR 2.31,95%CI 1.15-4.63)与生存率升高相关;无任何传统复温技术与28天生存相关。热水浴与较高复温速率相关(回归系数1.14,95%CI 0.75-1.53)。作者认为年龄、ADL和病情严重程度等背景因素对预后的贡献大于复温技术的选择。

要点

  • 本研究纳入371例核心体温≤32°C的成人意外性低体温患者,均接受传统复温治疗,无任何传统复温技术与28天生存相关。
  • 年龄(OR 0.97,95%CI 0.94-1.00)和SOFA评分(OR 0.73,95%CI 0.67-0.81)与28天生存率降低相关。
  • ADL独立与28天生存率升高相关(OR 2.31,95%CI 1.15-4.63)。
  • 热水浴与较高复温速率相关(回归系数1.14,95%CI 0.75-1.53)。
  • 作者认为年龄、ADL和病情严重程度等背景因素对预后的贡献大于复温技术的选择。

适用人群与场景

  • 年龄≥18岁、核心体温≤32°C、2019年12月1日至2022年3月31日期间转运至日本36家三级医院急诊科的意外性低体温患者。
  • 本二次分析纳入其中接受传统复温治疗(非ECMO相关复温)的患者。

诊断标准与关键阈值

  • 意外性低体温:核心体温≤32°C。
  • 入组ICE-CRASH研究条件:年龄≥18岁,2019年12月1日至2022年3月31日转运至日本36家三级医院急诊科。

研究设计与关键结果

  • 研究类型:ICE-CRASH多中心前瞻性观察研究的二次分析,日本36家三级医院参与;ICE-CRASH研究共纳入499例,本二次分析纳入371例接受传统复温治疗的患者。
  • 人群特征:中位年龄81岁,男性50.9%,中位初始体温28.8°C。
  • 主要终点(28天生存)多因素logistic回归:年龄OR 0.97(95%CI 0.94-1.00)和SOFA评分OR 0.73(95%CI 0.67-0.81)与生存率降低相关;ADL独立OR 2.31(95%CI 1.15-4.63)与生存率升高相关。
  • 无任何传统复温技术与28天生存相关。
  • 线性回归分析:热水浴与较高复温速率相关(回归系数1.14,95%CI 0.75-1.53)。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察研究的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,年龄、ADL和病情严重程度等背景因素对预后的贡献大于复温技术的选择。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Rewarming therapies for accidental hypothermia (AH) include extracorporeal membrane oxygenation (ECMO) and non-ECMO related (conventional) therapies. However, there are limited data available to inform the selection of conventional rewarming therapy. The aim of the present study was to explore what patients' factors and which rewarming therapy predicted favorable prognosis.

METHODS: This study is a secondary analysis of the Intensive Care with Extra Corporeal membrane oxygenation Rewarming in Accidentally Severe Hypothermia (ICE-CRASH) study, a multicenter prospective, observational study conducted in Japan. Enrolled in the ICE-CRASH study were patients aged ≥18 years with a core temperature of ≤32 °C who were transported to the emergency departments of 36 tertiary care hospitals in Japan between 1 December 2019 and 31 March 2022, among whom those who were rewarmed with conventional rewarming therapy were included in the present study. Logistic regression analysis was performed with 28-day survival as the objective variable; and seven factors including age, activities of daily living (ADL) independence, sequential organ failure assessment (SOFA) score, and each rewarming technique as explanatory variables. We performed linear regression analysis to identify whether each rewarming technique was associated with rewarming rate.

RESULTS: Of the 499 patients enrolled in the ICE-CRASH study, 371 were eligible for this secondary analysis. The median age was 81 years, 50.9% were male, and the median initial body temperature was 28.8 °C. Age (odds ratio [OR]: 0.97, 95% confidence interval [CI]: 0.94-1.00) and SOFA score (OR: 0.73, 95% CI: 0.67-0.81) were associated with lower survival, whereas ADL independence (OR: 2.31, 95% CI: 1.15-4.63) was associated with higher survival. No conventional rewarming therapy was associated with 28-day survival. Hot bath was associated with a high rewarming rate (regression coefficient: 1.14, 95% CI: 0.75-1.53).

CONCLUSION: No conventional rewarming therapy was associated with improved 28-day survival, which suggests that background factors such as age, ADL, and severity of condition contribute more to prognosis than does the selection of rewarming technique.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Sugiyama K, Nomura O, Irie J, et al. Effects of rewarming therapies on outcomes in accidental hypothermia: A secondary analysis of a multicenter prospective study. Am J Emerg Med. 2024. PMID: 38412669. doi:10.1016/j.ajem.2024.02.014

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。